Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 January 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 11 June 2026, providing investors with an up-to-date view of the stock’s fundamentals, returns, and technical outlook.

Surging past its previous peaks, Kwality Pharmaceuticals Ltd touched a new 52-week high of Rs 2520.45 on 10 Jun 2026, marking a remarkable 151.90% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained upward price action, setting the stage for a compelling momentum narrative.

Extending its recent rally, Kwality Pharmaceuticals Ltd surged 5.12% on 10 Jun 2026 to close at Rs 2,455.90, marking a fresh all-time high. This move comes amid a strong outperformance versus the Sensex, which gained a modest 0.54% on the same day.

Surging to an all-time high of Rs 2389.7 on 1 Jun 2026, Kwality Pharmaceuticals Ltd has demonstrated remarkable price momentum, rallying 151.11% over the past year against a Sensex decline of 7.98%. This milestone caps a sustained uptrend supported by a confluence of bullish technical indicators and robust quarterly earnings growth.

Kwality Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs. 2,389.70 on 1 June 2026, reflecting a remarkable journey of sustained growth and robust financial performance within the Pharmaceuticals & Biotechnology sector.

Kwality Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 Jan 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 31 May 2026, providing investors with the latest insights into its performance and outlook.

With a remarkable surge to Rs 2350 on 29 May 2026, Kwality Pharmaceuticals Ltd has reached a new 52-week and all-time high, propelled by a confluence of strong technical indicators and sustained price momentum.

Extending its recent rally, Kwality Pharmaceuticals Ltd surged to a fresh all-time high of Rs 2,323 on 29 May 2026, outperforming its sector and the broader market with a 4.52% gain on the day.

A 152.02% stock return in one year. A 70.5% growth in net profit over the same period. The gap between those two numbers — roughly 80 percentage points — is driven largely by the market’s willingness to pay more for each rupee of Kwality Pharmaceuticals Ltd’s earnings. That willingness is the story behind this micro-cap’s multibagger status.

Surging to an intraday peak of Rs 2315 on 25 May 2026, Kwality Pharmaceuticals Ltd has marked a significant milestone by reaching a fresh 52-week high. This rally, driven by a confluence of robust technical indicators and sustained price momentum, underscores the stock’s remarkable ascent over the past year, outpacing the broader market by a wide margin.

Kwality Pharmaceuticals Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 29 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

From a 52-week low of Rs 810.5 to a fresh high of Rs 2194.4 on 20 May 2026, Kwality Pharmaceuticals Ltd has more than doubled in value over the past year, delivering a remarkable 123.07% return. This surge comes amid a backdrop of mixed market conditions, with the Sensex trading below its 50-day moving average and hovering near its own 52-week low.

Kwality Pharmaceuticals Ltd has reached a significant milestone by touching an all-time high price of Rs. 2,194.40 on 20 May 2026, marking a remarkable phase in the company’s market performance and reflecting sustained investor confidence amid a bullish trend.

Kwality Pharmaceuticals Ltd has demonstrated a marked improvement in its financial performance for the quarter ended March 2026, shifting from an outstanding to a very positive financial trend. This robust quarterly showing is complemented by impressive stock returns that have significantly outpaced the broader Sensex index over multiple time horizons.